Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy

Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy

RAS mutations occur in approximately 20% of all cancers and given their clonality, key role as driver mutation, association with poor prognosis and undruggability, they represent attractive targets for immunotherapy. We have identified immunogenic peptides derived from codon 12 mutant RAS (G12A, G12...

Full description

Bibliographic Details
Main Authors: Renato B. Baleeiro, Louisa S. Chard Dunmall, Peng Liu, Shuangshuang Lu, Yuchun Lone, Nicholas R. Lemoine, Yaohe Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
RAS
neo-antigens
cancer immunotherapy
cancer vaccine
cancer peptides
T-cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.902709/full

Similar Items

Similar Items